Pramocaine
CARDIOVASCULAR SYSTEM
Also known as: pramocain, pramocaine hydrochloride, pramoxin, pramoxine, pramoxine HCl, pramoxine hydrochloride
Data last refreshed: (DrugCentral release 2024-11-01)
Key facts
Pramocaine is an ofp drug catalogued in DrugCentral. It was first approved by the FDA in 1976. DrugCentral lists 3 molecular targets, including SIGMAR1, Pgrmc1 and SCN1A|SCN2A|SCN3A. Recorded indications include Allergic otitis externa, Arthropod bite wound, Burn injury and Dry skin.
- Approval status: ofp (first approved 1976 by the FDA).
- Molecular targets: SIGMAR1, Pgrmc1 and SCN1A|SCN2A|SCN3A (3 listed in DrugCentral).
- Indications: Allergic otitis externa, Arthropod bite wound, Burn injury, Dry skin and Eruption of skin and others.
- ATC code: C05AD07 (Local anesthetics).
- Molecular formula: C17H27NO3; molecular weight 293.41 g/mol.
Indications & contraindications
Drug–disease relationships curated by DrugCentral (OMOP / SNOMED concepts).
Indications (21)
- Allergic otitis externa
- Arthropod bite wound
- Burn injury
- Dry skin
- Eruption of skin
- Hemorrhoids
- Inflammatory dermatosis
- Itching of ear
- Itching of skin
- Minor Bacterial Skin Infections
- Minor Skin Wound Pain
- Otitis externa
- Prevent Minor Bacterial Skin Infection
- Proctitis
- Pruritus ani
- Rectal pain
- Skin irritation
- Tinea corporis
- Tinea cruris
- Tinea pedis
- Wound
Contraindications (40)
- Abscess of intestine
- Acute tuberculosis
- Adrenal cortical hypofunction
- Anastomosis of intestine
- Anxiety
- Atrophoderma
- Benign prostatic hyperplasia
- Chronic heart failure
- Conduction disorder of the heart
- Contact dermatitis
- Denuded skin
- Diabetes mellitus
- Disorder of coronary artery
- Diverticulitis of gastrointestinal tract
- Fissure in skin
- Fungal ear infection
- Gastrointestinal fistula
- Herpes simplex
- Herpes zoster auricularis
- Hypertensive disorder
- Hyperthyroidism
- Hypothyroidism
- Infectious disease
- Kidney disease
- Measles
- Mycosis
- Nervousness
- Open wound
- Open-angle glaucoma
- Ophthalmic herpes simplex
- + 10 more
Mechanism & targets
Molecular targets (3)
| Target | Gene | Action | Activity |
|---|---|---|---|
| Sigma non-opioid intracellular receptor 1 | SIGMAR1 | unknown | Ki 7.29 |
| Membrane-associated progesterone receptor component 1 | Pgrmc1 | unknown | Ki 6.20 |
| Sodium channel alpha subunits; brain (Types I, II, III) | SCN1A|SCN2A|SCN3A | unknown | IC50 4.67 |
Regulatory approvals (1)
| Date | Agency | Marketed as | Applicant | Orphan |
|---|---|---|---|---|
| 1976-08-13 | FDA | — | SEBELA IRELAND LTD |
ATC classification
| ATC code | Therapeutic hierarchy |
|---|---|
C05AD07 | CARDIOVASCULAR SYSTEM › VASOPROTECTIVES › AGENTS FOR TREATMENT OF HEMORRHOIDS AND ANAL FISSURES FOR TOPICAL USE › Local anesthetics |
D04AB07 | DERMATOLOGICALS › ANTIPRURITICS, INCL. ANTIHISTAMINES, ANESTHETICS, ETC. › ANTIPRURITICS, INCL. ANTIHISTAMINES, ANESTHETICS, ETC. › Anesthetics for topical use |
Reported adverse-event signals
Strongest FDA FAERS disproportionality signals (log-likelihood ratio). A signal is a statistical association in spontaneous reports, not proof that the drug causes the event.
| MedDRA term | LLR |
|---|---|
| Macular degeneration | 1228.1 |
| Chronic sinusitis | 522.8 |
| Female genital tract fistula | 454.7 |
| Paraesthesia oral | 420.5 |
| Vaginal flatulence | 404.1 |
| Procedural pain | 395.5 |
| Proctitis | 364.4 |
| Radiculopathy | 358.4 |
| Vaginal discharge | 356.5 |
| Oral candidiasis | 253.3 |
| Frequent bowel movements | 213.6 |
| Colitis ulcerative | 199.2 |
Chemical structure
Full physicochemical, ADMET and 3D-structure analysis of Pramocaine is on its molecule page.
| Molecular formula | C17H27NO3 |
|---|---|
| Molecular weight | 293.41 g/mol |
| CAS number | 140-65-8 |
| InChIKey | DQKXQSGTHWVTAD-UHFFFAOYSA-N |
| PubChem CID | 4886 |
Frequently asked questions
Answers are generated from the structured data on this page, not written by hand.
What is Pramocaine used for?
DrugCentral lists the following indications for Pramocaine: Allergic otitis externa, Arthropod bite wound, Burn injury, Dry skin, Eruption of skin, Hemorrhoids, Inflammatory dermatosis and Itching of ear and others.
How does Pramocaine work?
Its molecular targets in DrugCentral include SIGMAR1, Pgrmc1 and SCN1A|SCN2A|SCN3A.
When was Pramocaine first approved?
Pramocaine was first approved by the FDA in 1976.
What is the chemical formula of Pramocaine?
Pramocaine has the molecular formula C17H27NO3 and a molecular weight of 293.41 g/mol.
Browse: all drugs starting with P · drug guides by category · protein targets A–Z.
Sources
- DrugCentral drug card 3487 — structure, indications, targets, approvals, pharmacologic classes (CC BY-SA 4.0)
- ChEMBL CHEMBL1198 — compound record and bioactivity
- PubChem CID 4886 — chemical identifiers
- DrugBank DB09345 — drug record
- FDA UNII 068X84E056 — substance identity
- DailyMed: FDA labels for Pramocaine — current prescribing information (label search)
- UniProt Q99720 (SIGMAR1) — target protein
- FDA Adverse Event Reporting System (openFDA FAERS) — adverse-event signals, as aggregated by DrugCentral
How this page is built: methodology · editorial policy & corrections.
For research and educational use only — not medical advice. This page is compiled automatically from public databases. It is not written or reviewed by a clinician. Do not start, stop or change any treatment based on it; consult a qualified healthcare professional. Spotted an error? See our corrections policy or email hello@molforge.ai.